| Allogeneic
|
from a donor other than
yourself and other than a
syngeneic twin |
| |
|
| Autologous |
from
yourself; your own |
| |
|
| Autoimmune
disease |
disease
induced by a situation in which your immune system develops
markers (antigens) against cells of your tissues or organs |
| |
|
| Bone
marrow abnormality |
aplasia,
myeloadysplasia |
| |
|
| Chemotherapy |
drugs that
induce cell death |
| |
|
| Clinical
research |
the
science of development, implementation and execution of clinical
studies, and the analysis and reporting of study results |
| |
|
| Clinical
study |
an
examination of the safety, efficacy and effectiveness of a
product or treatment strategy according to a written protocol |
| |
|
| Clinical
trial |
an
effort to try to evaluate the effect of a product or treatment
strategy according to a written protocol |
| |
|
| Combined
modality |
a
combination of compounds, products or strategies used together
as one treatment within a predefined time frame; for example,
chemotherapy combined with autologous and/or allogeneic reduced
intensity conditioning stem cell transplant |
| |
|
| Cord
Blood |
blood
retrieved from umbilical cords |
| |
|
| Cytotoxic |
toxic
to cells; induction of cell death |
| |
|
| Disseminated
|
distantly
spread out; metastatic |
| |
|
| Donor |
a
person who donates stem cells; you can be your own donor
(autologous) or someone else donates stem cells to you
for infusion (allogeneic) |
| |
|
| Dose-reduced
transplant |
reduced
intensity conditioning transplant; the preparative regimen (chemotherapy) does not
ablate marow; that means, that marrow could recover, also
without infusion of stem cells, but only after a long time |
| |
|
| Effectiveness |
refers
to the safety, efficacy and cost-efficiency of a treatment; that
means it is an indication for the effect of the treatment on
long-term outcome of the disease |
| |
|
| Efficacy |
degree
to which a treatment is able to induce a response to the
treatment |
| |
|
| Eligibility
|
describes
the criteria that need to be fulfilled to participate in a
study; these may involve demographics, disease and disease
stage, your condition, prior treatment, etc. |
| |
|
| G-CSF |
granulocyte
colony-stimulating factor; a compound that induces proliferation
of granulocytes |
| |
|
| Graft-versus-host-disease |
a
situation in which donor lymphocytes attack normal host cells |
| |
|
| Graft-versus-leukemia |
a
situation in which donor lymphocytes attack leukemia |
| |
|
| Graft-versus-tumor
|
a
situation in which donor lymphocytes attack tumor cells |
| |
|
| Granulocytes |
subset
of white blood
cells that protect against infection, are involved in wound
healing, etc. |
| |
|
| Good
Clinical Practice |
guidelines
defined by an international organization according to which
treatment should be performed when you are enrolled in a
clinical study |
| |
|
| Harvest |
collection
|
| |
|
| Hematological
malignancies |
Acute leukemia, chronic leukemia,
plasma cell cancer or Kahler's disease; lymphoma are sometimes
counted to hematological cancer |
| |
|
| Hematopoietic |
blood
cell producing |
| |
|
| HLA-typing |
examination of histocompatibility
leukocyte antigens; important procedure for finding an
allogeneic donor |
| |
|
| Hodgkin's
disease |
lymph
node cancer |
| |
|
| Immune
competent |
able
to induce an immune response; a lymphocyte is an immune
competent cell |
| |
|
| Immune
therapy |
therapy
with biologic agents or cells that can elicit an immune response
or produce immune markers |
| |
|
| Informed
consent |
document
to be signed by the patient and members of a treatment team that
explains the treatment, the study procedures, site effects,
benefits and risks to be expected from the treatment |
| |
|
| Leukapheresis |
procedure
by which white cells are collected from the blood of a donor by
a machine called apheresis machine |
| |
|
| Leukemia |
cancer
of white bone marrow cells; they may circulate in the blood as
white blood cells |
| |
|
| Lymphocytes |
subset
of white blood cells that elicit and are involved in an immune
response |
| |
|
| Lymphoma |
term
for non-Hodgkin lymphoma and/or Hodgkin's disease |
| |
|
| Lymph
node cancer |
Lymphoma |
| |
|
| Malignant
disease |
another
term for cancer or cancerous tumor |
| |
|
| Mini-transplant |
another
name for reduced intensity conditioning transplant |
| |
|
| Monocytes |
subset
of white blood cells that clear pathogens and damaged cells from
the blood stream and tissues |
| |
|
| Multiple
myeloma |
Disease
of Kahler; cancer of plasma cells; plasma cells are bone marrow
stem cells that produce immunoglobulines |
| |
|
| Myeloablative |
eradication
of all stem cells from the bone marrow such that bone marrow recovery could not occur without infusion of stem
cells |
| |
|
| Neuroblastoma |
embryonic neural cell cancer |
| |
|
| Non-hodgkin
lymphoma |
cancer
of lymphocytes in- and outside lymph nodes |
| |
|
| Non-myeloablative |
reduction
of the stem cell content of the bone marrow to a degree that some recovery might occur without infusion of stem cells |
| |
|
| Peripheral
blood progenitor cells |
bone
marrow cells mobilized into the blood |
| |
|
| Preparative
regimen |
chemotherapy
and/or radiotherapy administered as part of the transplant
procedure |
| |
|
| Protocol |
document
that describes all aspects of the treatment of a clinical study |
| |
|
| Recurrence |
disease
relapse;
the disease comes back after complete remission or complete response |
| |
|
| Relapse |
disease
recurrence; the disease comes back after complete
remission or complete response |
| |
|
| Safety |
refers
to the degree of side effects caused by a treatment; if few side
effects are induced the treatment is safe; if many of severe
side effects are induced the treatment may be unsafe |
| |
|
| Stem
cell |
undifferentiated
cell
that can proliferate indefinitely without dying |
| |
|
| Stem
cell transplant |
strictly,
the infusion of stem cells; broadly, the total
procedure of chemotherapy prior to transplant plus
infusion of stem cells |
| |
|
| Solid
tumors |
Cancers in which cells clup together |
| |
|
| Transplanter |
doctor
who can administer a stem cell transplant |
| |
|
| Vene |
blood
vessel of the venous system, which is the blood vessel system
that carries blood to your heart |